Eradication of HIV-1 latent reservoirs through therapeutic vaccination

Joshua Pankrac, Katja Klein, Jamie F S Mann

Research output: Contribution to journalReview article (Academic Journal)peer-review

Abstract

Despite the significant success of combination anti-retroviral therapy to reduce HIV viremia and save lives, HIV-1 infection remains a lifelong infection that must be appropriately managed. Advances in the understanding of the HIV infection process and insights from vaccine development in other biomedical fields such as cancer, imaging, and genetic engineering have fueled rapid advancements in HIV cure research. In the last few years, several studies have focused on the development of "Kick and Kill" therapies to reverse HIV latency and kick start viral translational activity. This has been done with the aim that concomitant anti-retroviral treatment and the elicited immune responses will prevent de novo infections while eradicating productively infected cells. In this review, we describe our perspective on HIV cure and the new approaches we are undertaking to eradicate the established pro-viral reservoir.

Original languageEnglish
Pages (from-to)45
JournalAIDS research and therapy
Volume14
Issue number1
DOIs
Publication statusPublished - 12 Sep 2017

Keywords

  • AIDS Vaccines/administration & dosage
  • Anti-HIV Agents/therapeutic use
  • CD4-Positive T-Lymphocytes/immunology
  • HIV Infections/immunology
  • HIV-1/immunology
  • Humans
  • Vaccination
  • Vaccines, Virus-Like Particle/immunology
  • Viremia/immunology
  • Virus Latency

Fingerprint Dive into the research topics of 'Eradication of HIV-1 latent reservoirs through therapeutic vaccination'. Together they form a unique fingerprint.

Cite this